BRAF Fusions (MSK, Cancer Discovery 2024) — MSK-IMPACT Tissue Panel

Overview

The large MSK-IMPACT tissue sequencing background cohort underlying the BRAF fusion tumor-agnostic study at Memorial Sloan Kettering Cancer Center. Contains 97,024 samples from 69,337 patients sequenced between January 2014 and November 2022 via MSK-IMPACT. Used to assess BRAF fusion prevalence across cancer types. A companion RNA fusion-panel cohort is available as braf_msk_archer_2024. PMID:38922339

Composition

  • 97,024 samples from 69,337 patients sequenced at MSK via MSK-IMPACT, MSK-ACCESS, and MSK-Fusion panels. PMID:38922339
  • 212 patients with oncogenic BRAF fusions (195 de novo, 17 detected post-targeted therapy) identified within this cohort. PMID:38922339
  • Covers 52 histologies; de novo BRAF fusion prevalence <1% across all cancers. PMID:38922339

Assays / panels (linked)

  • MSK-IMPACT targeted DNA sequencing (341–505 gene panels).
  • MSK-ACCESS plasma sequencing and MSK-Fusion RNA panel also included in screening. PMID:38922339

Papers using this cohort

  • PMID:38922339 — Tumor-agnostic genomic and clinical analysis of BRAF fusions identify actionable targets.

Notable findings derived from this cohort

  • De novo BRAF fusion prevalence was <1% (195/69,337); highest in pilocytic astrocytomas (56%), gangliogliomas, low-grade neuroepithelial tumors, and acinar cell carcinoma of the pancreas (each ≥5%). PMID:38922339
  • BRAF fusions were mutually exclusive with other MAPK pathway alterations. Co-alterations included TP53 mutations (22%), TERT mutations (18%), CDKN2A deletions (14%). PMID:38922339

Sources

This page was processed by crosslinker on 2026-05-04.